iZora's CEO identifies a "sweet spot" of three to five high-quality programs. This size is large enough to benefit from risk diversification but small enough to avoid losing focus and stretching resources thin. It provides a concrete framework for balancing ambition with manageable execution and capital requirements.

During capital-constrained periods, founders must be ruthless in their focus. Every dollar and hour should go towards "killer experiments"—those that directly accrue value and hit the specific milestones required for the next fundraising round. "Cool science" that doesn't advance these goals is a luxury companies can't afford.

In a market favoring asset-centric biotech, Springtide VC remains focused on platform companies. This countercyclical strategy mitigates the binary risk of single-asset failure and allows for multiple "shots on goal" and diverse business models, such as partnerships or becoming a drug developer.

Startups, especially in deep tech, often get stuck trying to keep all options open. The most effective way to force focus and enable progress is to definitively answer 'Who is this for?'. This shifts the team from building generic technology to building a specific product.

While a challenging fundraising market seems negative, it forces startups to operate with discipline. Unlike in frothy markets where companies expand based on hype, the current climate rewards tangible results. This compels a lean structure focused on high-value projects, creating a healthier long-term business model.

EG427 began by focusing narrowly on neurogenic bladder in spinal cord injury patients. This specific application proved the technology's potential, attracted investors, and enabled the company to later expand its pinpoint DNA medicine into a broader platform for neurological diseases.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

In biotech, early data is often ambiguous. Instead of judging programs on potential, leaders must prioritize based on the time and capital required to reach a clear 'yes' or 'no' outcome. Indefinite 'gray zone' projects drain resources that could fund a winner.

Rahul Aras learned from his first venture that combining a novel target, a new modality (gene therapy), and a unique delivery device created too many unknowns. At Iterion, he prioritized minimizing such variables to create a more manageable risk profile for investors and partners, focusing on a single core innovation.